Ajaz Khan, MD
Family Medicine · Copperhill, TNNPI 1043257645
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $540 and has fallen 78.1% since, to $118 in 2025.
Across 65 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$288
- GSK$149
- Abbott$149
- Takeda Pharmaceuticals U.S.A., Inc.$120
- Novo Nordisk$106
- Lilly USA, LLC$79
- plus $478 from 14 others
Across 26 payments — averaging $8870.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lexicon Pharmaceuticals, Inc.$176K
- Merck$55K
What the payments were for
- Food & beverage$1,369100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $288 |
| GSK | 5 | $149 |
| Abbott | 7 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $120 |
| Novo Nordisk | 5 | $106 |
| Lilly USA, LLC | 5 | $79 |
| Shield Therapeutics Inc | 2 | $72 |
| AbbVie | 4 | $68 |
| Astellas Pharma US Inc | 3 | $53 |
| Bayer | 2 | $46 |
| Amgen | 2 | $36 |
| Medtronic | 2 | $34 |
| Exact Sciences | 2 | $33 |
| Merck | 1 | $24 |
| Pfizer | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Novartis | 1 | $14 |
How this compares
$1,369 in reported general payments places this provider in the 60th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 117 | $134,625 |
| TrulicityDulaglutide | 56 | $112,460 |
| FarxigaDapagliflozin Propanediol | 99 | $108,003 |
| OzempicSemaglutide | 53 | $57,007 |
| MounjaroTirzepatide | 27 | $34,441 |
| JanuviaSitagliptin Phosphate | 24 | $34,111 |
| EliquisApixaban | 38 | $33,364 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $31,429 |
| TradjentaLinagliptin | 12 | $13,124 |
| Levemir FlexpenInsulin Detemir | 14 | $5,166 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $4,108 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,766 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $3,550 |
| Gabapentin | 193 | $3,106 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 23 | $2,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $17 | $147,749129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $79 | $146,90083 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $288 | $143,199154 claims |
| Novo NordiskOzempic | $106 | $57,00753 claims |
| MerckJanuvia | $24 | $34,11124 claims |
| PfizerEliquis | $23 | $33,36438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Copperhill
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
- Meredith SchweitzerAntioch$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.